LAK免疫支持治疗对慢性肾功能衰竭大鼠残余肾功能影响的研究

Study of Effect of LAK Therapy on Residual Renal Function in Rats with Chronic Kidney Failure

目的:研究LAK(Lymphokine-activated killer cells)免疫支持治疗对慢性肾功能衰竭(Chronic renal failure,CRF)机体肾功能的影响,以评估该治疗在CRF临床治疗中的应用前景。方法:对SD大鼠采用两步法行5/6肾脏切除术建立CRF动物模型,并制备LAK,在此基础上分别对CRF大鼠进行LAK治疗与生理盐水对照处理;对大鼠肾切术前后及LAK治疗后3周、6周血尿素氮(BUN)、肌酐(Cr)进行测定,并应用酶联免疫吸附试验(ELISA)测定血浆白细胞介素-1β(IL-1β)水平。结果:5/6肾脏切除术后,大鼠BUN、Cr及血浆IL-1β水平均显著升高(P<0.01);LAK治疗后3周、6周,BUN、Cr及血浆IL-1β水平较同期生理盐水对照处理组大鼠显著降低(P<0.01)。结论:LAK作为一种过继性细胞免疫支持治疗,可能在今后的CRF患者支持治疗中有着相当的临床应用前景。

Objective To investigate the effect of lymphokine- activated killer cells(LAK) therapy on residual renal function in the rats with chronic renal failure(CRF) so as to evaluate the clinical perspective of this therapy. Methods The rats with 5/6 nephrectomy served as experimental animal model and LAK were obtained in the meanwhile. Blood urea nitrogen(BUN) and creatinine(Cr) was determined and the serum interleukin - 1β (IL - 1 β) was analysed by ELISA method before or after 5/6 nephrectomy as well as 3 and 6 weeks after LAK therapy in both LAK therapy and control groups. Results The levels of BUN, Cr and serum IL- 1β increased significantly after 5/6 nephrectomy( P <0.01). However, the levels of BUN, Cr and serum IL- 1β in the rats with CRF treated by LAK were significantly( P <0.01) lower 3 or 6 weeks after LAK therapy than those in the control group. Conclusion LAK might have considerable chinial perspective in immunotherapy in the patients with CRF.